Meetings Management

Leaders in Conference and Event Management and Organisation

  • Increase font size
  • Default font size
  • Decrease font size


Join the conversation on Twitter – #MVADS2019

The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2019 will offer researchers a fresh forum to discuss this important topic in detail.

MVADS 2019 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.

Scientific Advisory Panel

Conference Chairman: Martin Bachmann (Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

Edmond J. Remarque (BPRC, Rijswijk, The Netherlands)
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Erik Lindblad (Brenntag Biosector, Copenhagen, Denmark)
Manmohan Singh (Takeda Vaccines Inc., Cambridge, Massachusetts, USA)
Heather Davis (Seqirus, Maidenhead, Berkshire, UK)
Derek O’Hagan (GSK, Rockville, Maryland, USA)
Adriana Baz Morelli (CSL Ltd, Melbourne, Australia)
Nathalie Garcon (BIOASTER Technology Research Institute, Lyon, France)
Niranjan Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)
Virgil Schijns (Wageningen Unviversity, The Netherlands)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Burkhard Becher (University of Zurich, Zurich, Switzerland)
Maria Lazaro (SEPPIC, Paris, France)
Geert Vanden Bossche (UNIVAC LLC, Belgium)
Chris Fox (IDRI, Seattle, USA)
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)
Stefan Jungbluth (EVI, Heidelberg, Germany)
Jeffrey A. Hubbell (University of Chicago, Chicago, Illinois, USA)
Behazine Combadiere (Cimi-Paris, Paris, France)
Ken Ishii (NIBIOHN/University of Osako, Osako, Japan)
Ofer Levy (Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)
Jean Haensler (Sanofi Pasteur, Marcy L’Etoile, France)
Matthew Heath (Allergy Therapeutics (UK) Ltd, Worthing, West Sussex, UK)
Markus Clemenz (Verapido Medical GmbH, Villingen-Schwenningen, Germany)

Conference Scope

Scientific Sessions:

  • Mechanistic Interpretations
  • Delivery
  • Formulation & Design
  • Modern Vaccines & Adjuvants
  • Safety
  • Regulation
  • Future Developments